ScreenerHero

FHTX Foghorn Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · foghorntx.com
2.090USD+6.09%Mkt Cap: 124.12M $P/E: —

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the Uni…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap124.12M USD
Enterprise Value-7.49M USD
Revenue (TTM)36.74M USD
Gross Profit-42.09M USD
Net Income (TTM)-74.28M USD
Revenue/Share0.55 USD
Last Price2.090 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees106
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.92
PEG—
EV/EBITDA0.11
EV/Revenue-0.20
P/S3.18
P/B-1.43
EPS (TTM)-0.96
EPS (Forward)-1.03
52W Range
1.7925% of range7.350
52W High7.350 USD
52W Low1.792 USD
Profitability
Gross Margin-114.57%
Oper. Margin-54.78%
EBITDA Margin-180.61%
Profit Margin-240.33%
ROE68.46%
ROA-37.50%
Growth
Revenue Growth112.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-86.10M USD
CapEx (TTM)50.00K USD
FCF Margin-141.42%
FCF Yield-41.86%
Net Debt-124.48M USD
Net Debt/EBITDA1.88
Balance Sheet
Debt/Equity-0.38
Current Ratio3.36
Quick Ratio3.31
Book Value/Sh-1.38 USD
Cash/Share2.82 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.000 USD
Upside (mean)+187.1%
Target Range2.000 USD – 14.00 USD
2.000+187.1% to mean14.00
# Analysts6
Ownership
Shares Out.59.39M
Float28.08M
Insiders14.13%
Institutions77.11%
Short Interest
Short Ratio4.9d
Short % Float6.10%
Short % Out.3.36%
Shares Short1.99M
Short (prev mo.)1.79M
Technical
SMA 505.050 (-58.6%)
SMA 2005.034 (-58.5%)
Beta3.01
S&P 52W Chg16.45%
Avg Vol (30d)987.02K
Avg Vol (10d)2.12M
Technical Indicators
RSI (14)18.4
MACD-0.8206
MACD Signal-0.6517
MACD Hist.-0.1690
BB Upper5.465 USD
BB Middle3.600 USD
BB Lower1.735 USD
BB Width103.63%
ATR (14)0.3897 USD
Vol Ratio (20d)0.73x